Axsome prevé alcanzar flujo de caja positivo con su plan operativo actual
- Axsome Therapeutics prevé contar con recursos suficientes para alcanzar un flujo de caja positivo con su plan operativo actual.
- Los ingresos del tercer trimestre de 2026 alcanzaron $259,7 millones, un 52% más interanual, con un ritmo anualizado superior a $1.000 millones.
- Estima ventas máximas potenciales superiores a $8.000 millones para Auvelity en depresión mayor.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.